FDA Panel Votes For Theravance’s Telavancin, Against Targanta’s Oritavancin
This article was originally published in The Pink Sheet Daily
Executive Summary
Telavancin’s safety concerns did not stand in its way, but oritavancin’s efficacy concerns in treating MRSA did.